Skip to main page content

• HOME
• Current Issue
• Archive
• Alerts
• About ASM
• Contact us
• Tech Support
• Journals.ASM.org

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services E-mail this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Aubry-Damon, H. Articles by Courvalin, P. Search for Related Content PubMed PubMed Citation Articles by Aubry-Damon, H. Articles by Courvalin, P.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, May 2002, p. 1571-1573, Vol. 46, No. 5
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.5.1571-1573.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

rpoB Mutation Conferring Rifampin Resistance in Streptococcus pyogenes

Hélène Aubry-Damon,^, Marc Galimand, Guy Gerbaud, and Patrice Courvalin^*

Unité des Agents Antibactériens, Institut Pasteur, 75724 Paris Cedex 15, France

Received 18 September 2000/ Returned for modification 30 March 2001/ Accepted 24 January 2002

Top Abstract Text References

 
Streptococcus pyogenes BM4478 and Staphylococcus aureus BM4479 were isolated from a patient undergoing rifampin therapy. High-level resistance to rifampin was due to the following mutations in the rpoB gene: Ser₅₂₂Leu in strain BM4478 and His₅₂₆Asn and Ser₅₇₄Leu in strain BM4479.

Top Abstract Text References

 
Streptococcus pyogenes is responsible for high rates of morbidity due to an increase in invasive group A streptococcal infections and bacteremia worldwide, with the most commonly reported predisposing factor being skin lesions (R. C. George, A. Efstratiou, M. A. Monnickendam, M. B. Mcevoy, G. Hallas, A. P. Johnson, and A. Tanna, Abstr. 39th Intersci. Conf. Antimicrob. Agents Chemother., abstr. 309, p. 658, 1999). S. pyogenes is also the leading cause of bacterial pharyngotonsillitis. An increase in macrolide resistance in this species (E. L. Kaplan, D. R. Johnson, and C. D. Rothermel, Abstr. 39th Intersci. Conf. Antimicrob. Agents Chemother., abstr. 535, p. 714, 1999) and the reduced efficacy of oral penicillin V in its eradication from upper respiratory tracts in children have led to the proposal of penicillin being used in combination with rifampin (9).

The mechanisms involved in rifampin resistance in S. pyogenes have not been investigated. In gram-positive bacteria, resistance appears to be due to mutational alterations of the intracellular target of the drug, the RNA polymerase ß subunit encoded by the rpoB gene (1, 3, 12). The mutations are generally clustered in a 702-bp fragment, from nucleotide positions 486 to 717 (Escherichia coli coordinates), corresponding to the rifampin resistance-determining (Rif) region in the center of the rpoB gene (1).

S. pyogenes BM4478 and Staphylococcus aureus BM4479, both resistant to high levels of rifampin (MIC, >256 µg/ml), were isolated in 1999 from a patient with a recurrent ulcer infection undergoing therapy with rifampin alone at the Hospital Henri Mondor, Créteil, France. The isolates remained susceptible to all antibiotics that are usually active against gram-positive cocci, except tetracycline for BM4478 and penicillin G and tetracycline for BM4479.

(An initial report of this work was presented at the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Ill., 16 to 19 December 2001 [H. Aubry-Damon, G. Gerbaud, and P. Courvalin, Abstr. 41st Intersci. Conf. Antimicrob. Agents Chemother., abstract C1-159, p. 82, 2001].)

We amplified by PCR the entire rpoB gene (Table 1, primer pair A) from BM4478 and CIP5641T, an antibiotic-susceptible S. pyogenes type strain (rifampin MIC = 0.008 µg/ml), and a portion of the rpoB gene (Table 1, primer pair F) corresponding to the Rif mutated region in previously studied bacterial genera (1, 2, 4, 8) from Staphylococcus aureus BM4479 and plasmid-free Staphylococcus aureus RN4220, which is susceptible to antibiotics (rifampin MIC = 0.008 µg/ml). The amplification products were cloned in the pCRII vector (Invitrogen) and sequenced on both strands with an automated sequencer (CEQ 2000 DNA Analysis system; Beckman Coulter).

View this table: [in this window] [in a new window]

TABLE 1. Oligonucleotides used to detect mutations in the rpoB genes

Relative to the susceptible strains CIP5641T and SF370 (accession number AE006480), S. pyogenes BM4478 had two base pair changes in the rpoB gene that resulted in amino acid substitutions (Fig. 1) as follows: in cluster I at position 522 (Ser₅₂₂Leu) and outside of the Rif region at position 722 (Gln₇₂₂His) (E. coli coordinates). The two mutational changes, His₅₂₆Asn in cluster I and Ser₅₇₄Leu in cluster II (E. coli coordinates), found in Staphylococcus aureus BM4479 have already been shown to confer high-level resistance and cross-resistance to the rifamycins (12). In Streptococcus pneumoniae and in Staphylococcus aureus, the His₅₂₆Asn mutation, when present alone, confers low-level resistance (3, 12). Few Ser₅₇₄Leu mutations were found in cluster II of rifampin-resistant E. coli (6). However, the level of resistance conferred was not investigated.

View larger version (48K): [in this window] [in a new window]

FIG. 1. Amino acid sequence comparison of the Rif region of the rpoB gene of E. coli, Staphylococcus aureus, S. pneumoniae, and S. pyogenes. Clusters I, II, and III are indicated by a double line above the alignment. Dots indicate gaps introduced to optimize the alignment. Residues where substitutions are known to be involved in rifampin resistance are in bold. Mutations leading to rifampin resistance in S. pyogenes BM4478 and in Staphylococcus aureus BM4479 are indicated by double and single upward-pointing arrows, respectively.

To determine the role of the two alterations in S. pyogenes BM4478, purified PCR products (1 µg), each containing a single mutation, were added to rifampin-susceptible competent cells (5) of S. pneumoniae CP1000 (rifampin MIC = 0.023 µg/ml), and transformants were selected on rifampin at 10 µg/ml. The TCA/TTA (Ser₅₂₂Leu) mutation was amplified as part of a 520-bp PCR product obtained with primer pair B and mutation CAA/CAC (Gln₇₂₂His) was amplified as part of a 609-bp PCR product obtained with primer pair C (Table 1). The corresponding PCR products were also amplified from DNA of susceptible strain CIP5641T. The DNA of two transformants from each experiment was amplified and sequenced using primer pairs D and E (Table 1) to screen positions 522 and 722, respectively. Only transformation with the 520-bp PCR product containing the TTA mutation yielded resistant colonies at a frequency (Table 2) compatible with monogenic transformation (10). In the remaining experiments resistant derivatives of the recipient strain with mutations outside of the 370- and 210-bp portions sequenced were obtained at a frequency of ca. 10^-6. These data indicate that in S. pyogenes BM4478 rifampin resistance was due to the Ser₅₂₂Leu substitution located in cluster I. Mutations at this position also lead to high levels of resistance in Staphylococcus aureus (1), E. coli (4), Neisseria meningitidis (2), and Mycobacterium tuberculosis (8).

View this table: [in this window] [in a new window]

TABLE 2. Transformation of S. pneumoniae CP1000 with PCR-amplified DNA from BM4478 and CIP5641T

Interestingly, the substitutions in S. pyogenes and Staphylococcus aureus clinical isolates were different. Staphylococcus aureus BM4479 probably acquired high-level rifampin resistance in two steps. Rifampin resistance emerges easily in Staphylococcus aureus, in particular in methicillin-resistant strains (1). The occurrence of multiple mutations may be explained by epidemic dissemination of strains and their frequent exposure to rifampin. The mutations in BM4478 and BM4479 were clustered from nucleotide positions 522 to 526 (E. coli coordinates), suggesting that substitution of the corresponding amino acids in cluster I of S. pyogenes, like in E. coli, prevents the binding of rifampin to RNA polymerase (11). It has been shown in E. coli that residues 516 to 540 are part of the target of rifampin and participate with residues 1065 and 1237 in the formation of the initiation site when the ß subunit is assembled in the RNA polymerase complex (7).

This study suggests that, as in Staphylococcus aureus, cluster I in the central Rif region is the primary target for rifampin in S. pyogenes.

 
This work was supported in part by a Bristol-Myers Squibb Unrestricted Biomedical Research Grant in Infectious Diseases.

 
* Corresponding author. Mailing address: Unité des Agents Antibactériens, Institut Pasteur, 25 rue du Docteur Roux, 75724 Paris Cedex 15, France. Phone: 33 1 45 68 83 20. Fax: 33 1 46 68 83 19. E-mail: pcourval{at}pasteur.fr.

Present address: Département des Maladies Infectieuses, Institut de Veille Sanitaire, 12 rue du Val d'Osne, 94415 Saint Maurice, France.

Top Abstract Text References

 

1
1. Aubry-Damon, H., C. J. Soussy, and P. Courvalin. 1998. Characterization of mutations in the rpoB gene that confer rifampin resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 42:2590-2594.[Abstract/Free Full Text]
2
2. Carter, P. E., F. J. R. Abadi, D. E. Yakubu, and T. H. Pennington. 1994. Molecular characterization of rifampin-resistant Neisseria meningitidis. Antimicrob. Agents Chemother. 38:1256-1261.[Abstract/Free Full Text]
3
3. Enright, M., P. Zawadski, P. Pickerill, and C. G. Dowson. 1998. Molecular evolution of rifampicin resistance in Streptococcus pneumoniae. Microb. Drug Resist. 4:65-70.[Medline]
4
4. Jin, D. J., and C. A. Gross. 1988. Mapping and sequencing of mutations in the Escherichia coli rpoB gene that lead to rifampicin resistance. J. Mol. Biol. 202:45-58.[CrossRef][Medline]
5
5. Morrison, D. A., M.-C. Trombe, M. K. Hayden, G. A. Waszak, and J.-D. Chen. 1984. Isolation of transformation-deficient Streptococcus pneumoniae mutants defective in control of competence using insertion-duplication mutagenesis with the erythromycin resistance determinant of pAMß1. J. Bacteriol. 159:870-876.[Abstract/Free Full Text]
6
6. Severinov, K., M. Soushko, A. Goldfarb, and V. Nikiforov. 1993. Rifampicin region revisited. J. Biol. Chem. 268:14820-14825.[Abstract/Free Full Text]
7
7. Severinov, K., A. Mustaev, E. Severinova, M. Koslov, S. A. Darst, and A. Goldfarb. 1995. The beta subunit Rif-cluster I is only angstroms away from the active center of Escherichia coli RNA polymerase. J. Biol. Chem. 270:29428-29432.[Abstract/Free Full Text]
8
8. Taniguchi, H., H. Aramaki, Y. Nikaido, Y. Mizuguchi, M. Nakamura, T. Koga, and S. Yoshida. 1996. Rifampicin resistance and mutation of the rpoB gene in Mycobacterium tuberculosis. FEMS Microbiol. Lett. 144:103-108.[CrossRef][Medline]
9
9. Tanz, R. R., T. Stanford, and T. Schulman. 1985. Penicillin plus rifampin eradicates pharyngeal carriage of group A streptococci. J. Pediatrics 106:876-880.[CrossRef][Medline]
10
10. Tiraby, G., and M. S. Fox. 1973. Marker discrimination in transformation and mutation of pneumococcus. Proc. Natl. Acad. Sci. USA 70:3541-3545.[Abstract/Free Full Text]
11
11. Wehrli, W. 1983. Rifampin: mechanisms of action and resistance. Rev. Infect. Dis. 5(Suppl. 3):S407-S411.[Medline]
12
12. Wichelhaus, T. A., V. Schäfer, V. Brade, and B. Böddinghaus. 1999. Molecular characterization of rpoB mutations conferring cross-resistance to rifamycins on methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 43:2813-2816.[Abstract/Free Full Text]

---

Antimicrobial Agents and Chemotherapy, May 2002, p. 1571-1573, Vol. 46, No. 5
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.5.1571-1573.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

This article has been cited by other articles:

• Rothstein, D. M., Farquhar, R. S., Sirokman, K., Sondergaard, K. L., Hazlett, C., Doye, A. A., Gwathmey, J. K., Mullin, S., van Duzer, J., Murphy, C. K. (2006). Efficacy of Novel Rifamycin Derivatives against Rifamycin-Sensitive and -Resistant Staphylococcus aureus Isolates in Murine Models of Infection. Antimicrob. Agents Chemother. 50: 3658-3664 [Abstract] [Full Text]  
• Mullin, S., Rothstein, D. M., Murphy, C. K. (2006). Activity of Novel Benzoxazinorifamycins against Rifamycin-Resistant Streptococcus pyogenes. Antimicrob. Agents Chemother. 50: 1908-1909 [Full Text]  
• Xia, M., Suchland, R. J., Carswell, J. A., Van Duzer, J., Buxton, D. K., Brown, K., Rothstein, D. M., Stamm, W. E. (2005). Activities of Rifamycin Derivatives against Wild-Type and rpoB Mutants of Chlamydia trachomatis. Antimicrob. Agents Chemother. 49: 3974-3976 [Abstract] [Full Text]  
• Ferrandiz, M. J., Ardanuy, C., Linares, J., Garcia-Arenzana, J. M., Cercenado, E., Fleites, A., de la Campa, A. G., the Spanish Pneumococcal Infection Study Network, (2005). New Mutations and Horizontal Transfer of rpoB among Rifampin-Resistant Streptococcus pneumoniae from Four Spanish Hospitals. Antimicrob. Agents Chemother. 49: 2237-2245 [Abstract] [Full Text]  
• Yu, J., Wu, J., Francis, K. P., Purchio, T. F., Kadurugamuwa, J. L. (2005). Monitoring in vivo fitness of rifampicin-resistant Staphylococcus aureus mutants in a mouse biofilm infection model. J Antimicrob Chemother 55: 528-534 [Abstract] [Full Text]  
• Achour, W., Guenni, O., Fines, M., Leclercq, R., Ben Hassen, A. (2004). rpoB Mutations in Streptococcus mitis Clinical Isolates Resistant to Rifampin. Antimicrob. Agents Chemother. 48: 2757-2759 [Abstract] [Full Text]  
• Enne, V. I., Delsol, A. A., Roe, J. M., Bennett, P. M. (2004). Rifampicin resistance and its fitness cost in Enterococcus faecium. J Antimicrob Chemother 53: 203-207 [Abstract] [Full Text]  
• Kim, M., Wolff, E., Huang, T., Garibyan, L., Earl, A. M., Battista, J. R., Miller, J. H. (2004). Developing a Genetic System in Deinococcus radiodurans for Analyzing Mutations. Genetics 166: 661-668 [Abstract] [Full Text]  

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services E-mail this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Aubry-Damon, H. Articles by Courvalin, P. Search for Related Content PubMed PubMed Citation Articles by Aubry-Damon, H. Articles by Courvalin, P.